Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review by Cooper, Janine A. et al.
Interventions to improve the appropriate use of polypharmacy in
older people: a Cochrane systematic review
Cooper, J. A., Cadogan, C. A., Patterson, S. M., Kerse, N., Bradley, M. C., Ryan, C., & Hughes, C. M. (2015).
Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review.
BMJ Open, 5(12), [e009235]. DOI: 10.1136/bmjopen-2015-009235
Published in:
BMJ Open
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2015 The Authors
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
Interventions to improve the
appropriate use of polypharmacy in
older people: a Cochrane systematic
review
Janine A Cooper,1 Cathal A Cadogan,1 Susan M Patterson,2 Ngaire Kerse,3
Marie C Bradley,1 Cristín Ryan,1 Carmel M Hughes1
To cite: Cooper JA,
Cadogan CA, Patterson SM,
et al. Interventions to improve
the appropriate use of
polypharmacy in older
people: a Cochrane
systematic review. BMJ Open
2015;5:e009235.
doi:10.1136/bmjopen-2015-
009235
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-009235).
JAC and CAC are joint first
authors.
Received 29 June 2015
Revised 28 October 2015
Accepted 30 October 2015
1School of Pharmacy,
Queen’s University Belfast,
Belfast, UK
2Belfast, UK
3Department of General
Practice and Primary Health
Care, University of Auckland,
Auckland, New Zealand
Correspondence to
Professor Carmel M Hughes;
c.hughes@qub.ac.uk
ABSTRACT
Objective: To summarise the findings of an updated
Cochrane review of interventions aimed at improving
the appropriate use of polypharmacy in older people.
Design: Cochrane systematic review. Multiple
electronic databases were searched including
MEDLINE, EMBASE and the Cochrane Central Register
of Controlled Trials (from inception to November
2013). Hand searching of references was also
performed. Randomised controlled trials (RCTs),
controlled clinical trials, controlled before-and-after
studies and interrupted time series analyses reporting
on interventions targeting appropriate polypharmacy in
older people in any healthcare setting were included if
they used a validated measure of prescribing
appropriateness. Evidence quality was assessed using
the Cochrane risk of bias tool and GRADE (Grades of
Recommendation, Assessment, Development and
Evaluation).
Setting: All healthcare settings.
Participants: Older people (≥65 years) with ≥1
long-term condition who were receiving polypharmacy
(≥4 regular medicines).
Primary and secondary outcome measures:
Primary outcomes were the change in prevalence of
appropriate polypharmacy and hospital admissions.
Medication-related problems (eg, adverse drug
reactions), medication adherence and quality of life
were included as secondary outcomes.
Results: 12 studies were included: 8 RCTs, 2 cluster
RCTs and 2 controlled before-and-after studies.
1 study involved computerised decision support and
11 comprised pharmaceutical care approaches across
various settings. Appropriateness was measured using
validated tools, including the Medication
Appropriateness Index, Beers’ criteria and Screening
Tool of Older Person’s Prescriptions (STOPP)/
Screening Tool to Alert doctors to Right Treatment
(START). The interventions demonstrated a reduction
in inappropriate prescribing. Evidence of effect on
hospital admissions and medication-related problems
was conflicting. No differences in health-related quality
of life were reported.
Conclusions: The included interventions
demonstrated improvements in appropriate
polypharmacy based on reductions in inappropriate
prescribing. However, it remains unclear if
interventions resulted in clinically significant
improvements (eg, in terms of hospital admissions).
Future intervention studies would benefit from available
guidance on intervention development, evaluation and
reporting to facilitate replication in clinical practice.
INTRODUCTION
The WHO has predicted that the number of
older people (conventionally deﬁned as
≥65 years) worldwide will reach 1.5 billion by
2050.1 2 This population growth poses signiﬁ-
cant challenges for healthcare systems, as
Strengths and limitations of this study
▪ The updated Cochrane review that is summarised
in this paper used systematic and rigorous
methods to identify, appraise and synthesise
available evidence for the effectiveness of inter-
ventions aimed at improving appropriate poly-
pharmacy for older patients.
▪ No language restrictions were placed on the
search strategy and no apparent publication bias
was detected.
▪ The included studies were limited by their small
sample sizes and poor quality owing to risks of
bias, with little opportunity to pool data.
▪ Despite improvements in appropriate prescribing,
it must be noted that assessments were based
on surrogate markers of appropriate polyphar-
macy and the clinical significance of these
improvements in terms of other relevant out-
comes, for example, hospital admissions, is
unclear.
▪ Several studies focused on reducing the number
of medications, rather than improving the overall
appropriateness of prescribing, including
underprescribing.
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older people use a disproportionate amount of health-
care resources (eg, medications).3 4
Although there is no single agreed deﬁnition of the
term ‘polypharmacy’,5 6 this has been described as the
use of four or more medications.7 The potential for
negative outcomes with the use of multiple medications
in older people is well documented (eg, adverse drug
events (ADEs), non-adherence, drug interactions).8 9
A critical objective that poses considerable challenges
for healthcare professionals (HCPs) is to obtain a
balance between aggressively treating diseases and avoid-
ing medication-related harm.10
Polypharmacy has been identiﬁed as the principal
determinant of potentially inappropriate prescribing
(PIP) in older people.11 The term PIP encompasses
overprescribing, misprescribing and underprescribing.12
Underprescribing is an important clinical issue because
patients with polypharmacy have an increased likelihood
of not receiving potentially beneﬁcial, clinically indi-
cated medications compared with patients receiving
fewer medications.13 Accordingly, a range of assessment
tools have been developed to identify PIP in older
people and to optimise prescribing.14
Despite the potential for negative consequences in
older patients receiving polypharmacy, there is increas-
ing acceptance that the prescribing of multiple medica-
tions can be appropriate, and under certain
circumstances, should be encouraged.15 16 Thus, poly-
pharmacy can refer to the prescribing of many drugs
(appropriately) or too many drugs (inappropriately).16
Achieving appropriate polypharmacy involves prescrib-
ing the correct drugs under the appropriate circum-
stances to treat the right diseases. Ensuring appropriate
polypharmacy is of considerable importance because
PIP is highly prevalent in older people and has consider-
able cost implications for healthcare systems.11 17
The updated Cochrane review that is summarised in
this paper18 sought to determine the effectiveness of
interventions aimed at improving appropriate polyphar-
macy in older people. A recent Cochrane publication,
which consisted of an overview of systematic reviews,
highlighted that few reviews have considered the impli-
cations of polypharmacy on interventions seeking to
improve safe and effective medicine use by consumers,
including patients and their carers.19
METHODS
This systematic review followed the Cochrane
Collaboration methodology, and is available from the
Cochrane Library.18
Inclusion criteria
This review looked at interventions in any setting that
targeted older people (≥65 years) who had more than
one long-term medical condition and were receiving
polypharmacy (≥4 regular medications).
Randomised controlled trials (RCTs), including
cluster RCTs (cRCTs), non-randomised controlled clin-
ical trials, controlled before-and-after studies (CBAs)
and interrupted time series (ITS) studies meeting the
Effective Practice and Organisation of Care (EPOC) spe-
ciﬁcation20 were eligible for inclusion. Any type of inter-
vention that aimed to improve appropriate
polypharmacy in any healthcare setting was eligible for
inclusion. With the exception of ITS design, studies had
to compare the intervention against usual care as
deﬁned by the study. Interventions studies that focused
on people with single long-term conditions or who were
receiving short-term polypharmacy, for example, chemo-
therapy, were excluded. No language restrictions were
applied.
Outcome measures
Primary outcomes were the change in the prevalence of
appropriate polypharmacy and the number of hospital
admissions. As there is no universally applicable tool to
assess polypharmacy appropriateness in older people,
validated measures of inappropriate prescribing (eg,
Beers’ criteria21 and the Medication Appropriateness
Index (MAI)22) were used as surrogate markers. Studies
using expert opinion alone to determine medication
appropriateness were excluded.
The following secondary outcomes were included:
medication-related problems (eg, adverse drug reactions,
medication errors); medication adherence;
health-related quality of life (assessed by a validated
method).
Search methods for identification of studies
Search strategies (see full review18) comprised keywords
and controlled vocabulary such as MeSH (medical
subject headings). The following electronic databases
were searched for primary studies (all records through
to November 2013): Evidence-Based Medicine Reviews,
Cochrane Central Register of Controlled Trials, Ovid SP,
Health Technology Assessment, National Health Service
Economic Evaluation Database, Cochrane Methodology
Register, American College of Physicians Journal Club,
the Joanna Briggs Institute, MEDLINE, EMBASE,
CINAHL, EBSCO Host, PsycINFO.
Related systematic reviews were identiﬁed through the
Cochrane Database of Systematic Reviews and Database
of Abstracts of Reviews of Effects. Authors were con-
tacted for further information where necessary.
Data screening and extraction
The retrieved titles and abstracts were screened inde-
pendently by two authors against inclusion criteria.
Where uncertainty occurred, full-text articles were
retrieved and assessed. Any remaining uncertainty or dis-
agreement was resolved by consensus through discussion
with another author. Data were extracted independently
by two authors.
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Assessment of risk of bias
Two authors independently assessed risk of bias using
the Cochrane Collaboration’s assessment tool23 and
used GRADE (Grades of Recommendation, Assessment,
Development and Evaluation) to assess the quality of the
evidence for each primary outcome for which data were
pooled.24
Data analysis
Intervention effect was measured using validated assess-
ment tools of prescribing appropriateness (eg, sum-
mated MAI, Beers’ criteria). The mean and SD were
calculated for summated MAI and number of Beers’
drugs postintervention in each study’s intervention and
control groups. Where available, the mean change (and
SD) from pre to post was determined in the intervention
and control group. Based on these numbers, the mean
differences were calculated and results presented with
95% CIs. Estimates for dichotomous outcomes from
individual studies are presented as risk ratios with 95%
CIs.
If at least two studies were homogeneous in terms of
participants, interventions and outcomes, the results
were pooled in a meta-analysis. In the presence of statis-
tical heterogeneity (I2 statistic >50%), a random-effects
model was applied for meta-analysis. In the absence of
statistical heterogeneity, a ﬁxed-effects model was used.
Sensitivity analyses were conducted for studies with a
high risk of bias or a unit of analysis error. Where
outcome data could not be combined, a narrative
summary was reported. Reporting bias was examined
using risk of bias tables and funnel plots corresponding
to meta-analysis of the primary outcome to assess poten-
tial publication bias. Data analysis was conducted using
RevMan V.5.2.
RESULTS
Results of the search
Figure 1 provides an overview of the search. In this
update, two studies were identiﬁed and added,25 26
bringing the total number of included studies to 12. It
was not possible to include data from these two studies
in any meta-analysis because data were skewed or partici-
pants were not considered to be homogeneous with
other study populations.
The included studies consisted of eight RCTs,25–32 two
cRCTs33 34 and two CBAs.35 36 In total, 22 438 older
patients were involved, the majority of whom were
female (65.6%). On average, patients were 76 years old
(based on 12 studies) and receiving nine medicines at
baseline (based on 11 studies).
The studies were conducted in three types of settings
(table 1): hospital (outpatient clinics);27 29 30 hospital/
care home interface;28 inpatient setting;25 26 31 primary
care;32 34 nursing homes.33 35 36 The studies were
carried out in ﬁve countries: Australia (two studies),
Belgium (two studies), Canada (two studies), Ireland
(one study) and the USA (ﬁve studies).
Description of interventions
All interventions were classiﬁed as organisational accord-
ing to EPOC deﬁnitions.
Eleven studies examined complex, multifaceted,
pharmaceutical care-based interventions in various set-
tings, using validated assessment criteria to give recom-
mendations on improving the appropriateness of
prescribing. In all settings, pharmaceutical care (ie,
responsible provision of drug therapy to achieve deﬁni-
tive outcomes that improve patients’ quality of life37) was
commonly provided by pharmacists working closely with
other HCPs.
The models of pharmaceutical care provided were
complex and variable. For example, pharmacists con-
ducted independent medication reviews either using
patient notes28 33 or with patients during a face-to-face
encounter.27 29–32 34 In other cases, recommendations
from medication reviews were followed up with prescri-
bers and other HCPs.27–29 31 33
Patient education was provided as part of the interven-
tion in four studies involving face-to-face interventions.
Patients were given information about their prescribed
medications (eg, administration) and specialised
Figure 1 PRISMA flow chart: risk of bias in included studies
(n=12).
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Table 1 Characteristics of included studies
Study and
design Study participants and setting Duration and follow-up Intervention elements Outcomes
Hanlon
et al29
RCT
208 participants (105 intervention,
103 control), Veteran Affairs Medical
Centre, USA
Duration: unclear.
Follow-up: 3 and
12 months after
randomisation
Medication review, therapeutic
recommendations, patient education
Prescribing appropriateness (MAI), HRQoL,
patients’ self-reported medication
compliance and knowledge, potential
ADEs, participant satisfaction
Bucci
et al27
RCT
80 participants (39 intervention, 41
control), university hospital clinic,
Canada
Duration: unclear
Follow-up: 1 month
Medication review, therapeutic
recommendations, provision of
medication-related information
Prescribing appropriateness (MAI), rating of
pharmaceutical care activities (Purdue
Pharmacist Directive Guidance score)
Tamblyn
et al34
RCT
107 primary care physicians,
Canada
Duration: 13 months
Follow-up: terminated
after an inappropriate
prescription had been
initiated or discontinued
Computerised decision support; computer
system alerted prescribers of 159 clinically
relevant prescribing problems among the
elderly (McLeod criteria), the nature of the
problem, possible consequences and
suggested alternative therapy
Initiation and discontinuation rates of 159
prescription-related problems (McLeod
criteria)
Taylor
et al32
RCT
69 participants (33 intervention, 36
control), community-based family
medicine clinics, USA
Duration: 12 months
Follow-up: 12 months
Medication review, therapeutic
recommendations, therapeutic monitoring,
education of patients and healthcare
professionals
Prescribing appropriateness (MAI),
hospitalisations and emergency
department visits, medication
misadventures, medication compliance,
quality of life
Crotty
et al33
cRCT
154 participants (100 intervention
and internal control, 54 external
control), high-level residential aged
care facilities, Australia
Duration: 2 case
conferences 6 to
12 weeks apart
Follow-up: 3 months
Medication review, multidisciplinary case
conference, development of a problem list
Prescribing appropriateness (MAI),
residents’ behaviour (Nursing Home
Behaviour Problem Scale), monthly drug
costs
Crotty
et al28
RCT
110 participants (56 intervention, 54
control), hospital/long-term
residential care facility interface,
Australia
Duration: unclear
Follow-up: 8 weeks
Transfer of medication-related information
to care providers in long-term care
facilities, evidence-based medication
review, case conference
Prescribing appropriateness (MAI), hospital
usage (unplanned visits to the emergency
department and hospital readmissions),
ADEs, falls, worsening of mobility
behaviours, pain and increasing confusion
Schmader
et al30
RCT
834 participants (430 intervention,
404 control),
Veterans Affairs hospitals, USA
Duration: 12 months
Follow-up: 12 months
after randomisation
Medication review, therapeutic evaluation
and management protocols
Prescribing appropriateness (MAI, Beers’
list), adverse drug reactions, serious
adverse drug reactions, polypharmacy,
medication under use
Trygstad
et al36
CBA
Medicaid-dependent nursing home
residents, USA
Duration: 6 months
Follow-up: 3 months
Medication review, therapeutic
recommendations
Prescribing appropriateness (Beers’ list),
number of PAL alerts, potential medication
problems
Spinewine
et al31
RCT
186 participants (96 intervention, 90
controls), university teaching
hospital, Belgium
Duration: from admission
to discharge
Follow-up: 1, 3 and
12 months
Medication review, pharmaceutical care
plan, therapeutic recommendations,
information provision to healthcare
professionals, patient/carer education,
communication with GP
Prescribing appropriateness (MAI, Beers’
list, ACOVE), mortality, hospitalisation
(readmission or visit to an emergency
department), medication use (including
unnecessary drug use), satisfaction with
information provided at admission and
discharge
Continued
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medication scheduling tools (eg, monitored dosage
systems) to encourage adherence.27 29 31 32
Education was also provided to prescribers and other
HCPs involved in the multidisciplinary team as part of
the intervention in ﬁve studies.27–29 31 33
The only unifaceted study34 examined computerised
decision support (CDS) provided to general practi-
tioners in their own practices.
The timing of intervention provision was variable.
A number of interventions were delivered at speciﬁc
time points, for example, hospital admission, attendance
at outpatient clinics,27 29 30 32 nursing home visits,33 35 36
hospital discharge to a nursing home.28 In other cases,
interventions were delivered over a period of time, such
as during hospital inpatient stay and at discharge.30 31
Risk of bias in included studies
The included studies showed evidence of potential bias
(ﬁgure 2). Only three studies showed evidence of alloca-
tion concealment25 28 33 and only one study demon-
strated protection against contamination.33
Funnel plots of postintervention estimates of the
change in MAI and summated MAI showed little evi-
dence of publication bias.18
GRADE approach to quality assessment
Based on GRADE,24 the overall quality of evidence for
each primary outcome for which data were included in
a meta-analysis was rated as ‘low’ or ‘very low’ (table 2).
Although all studies included in the meta-analyses
involved randomisation, and, where assessed, no evi-
dence of publication bias was found,18 the quality of evi-
dence was downgraded for each outcome based on
other GRADE considerations (ie, study limitations, con-
sistency of effect, imprecision, indirectness).
Prevalence of appropriate use of polypharmacy
The primary outcome of interest was the change in the
prevalence of appropriate polypharmacy. Seven validated
measures of prescribing appropriateness were used in
the included studies, either alone or in combination.
Medication Appropriateness Index
The MAI was used in three ways to assess the appropri-
ateness of polypharmacy. First, data from four studies
(210 intervention participants, 214 control participants)
were pooled in a meta-analysis using the change in sum-
mated MAI score from baseline to follow-up.27 28 31 33
There was a greater overall reduction in the mean
change in summated MAI score in the intervention
group compared with the control (mean difference
−6.78, 95% CI −12.34 to −1.22; table 2). There was
marked heterogeneity between the studies (I2=96%,
p<0.0001). Sensitivity analyses in which one study with a
unit of analysis error (nursing homes were the unit of
randomisation but the analysis was conducted at patient
level)33 and another study with a large effect size and
high risks of bias31 were removed from analysis showed
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consistent changes in summated MAI with variable
effects on heterogeneity (table 2).
Second, postintervention pooled data from ﬁve
studies27–31 (488 intervention participants, 477 control
participants) showed a lower summated MAI score
(mean difference −3.88, 95% CI −5.40 to −2.35) in the
intervention group compared with the control group
(table 2). There was little evidence of heterogeneity
between these estimates (I2=0%). This was consistent
with the ﬁndings of Gallagher et al,25 which were not
included in the meta-analysis because the data were
skewed.
Third, one study32 expressed the MAI score as the
number of inappropriate prescriptions. The percentage
of inappropriate prescriptions decreased in all MAI
domains (n=10) in the intervention group and increased
in ﬁve domains in the control group. These data could
not be included in a meta-analysis.
Beers’ criteria
Pooled data from two studies30 31 (298 intervention par-
ticipants, 288 control participants) showed that interven-
tion group participants were prescribed fewer Beers’
drugs than control group participants postintervention
(mean difference −0.1, 95% CI −0.28 to 0.09; I2=89%;
table 2).
Spinewine et al31 also reported the proportion of
patients taking one or more Beers’ drugs preinterven-
tion and postintervention. Similar improvements were
reported in the proportion of intervention and control
group patients receiving one or more Beers’ drugs
between hospital admission and discharge (OR 0.6, 95%
CI 0.3 to 1.1). As this was the only study to report the
results in this format, meta-analysis was not possible.
McLeod criteria
One study used the McLeod criteria38 to identify the ini-
tiation and discontinuation rates of 159 prescription-
related problems.34 The reported relative rate of initi-
ation of inappropriate prescriptions for the intervention
group was 0.82 (95% CI 0.69 to 0.98). However, the
intervention did not appear to have an effect on the
relative rate of discontinuation of pre-existing
prescription-related problems (1.06, 95% CI 0.89 to
1.26). Meta-analysis was not possible as these criteria
were not used in other studies.
STOPP and START criteria
Two studies25 26 used the Screening Tool of Older
Person’s Prescriptions (STOPP) criteria to screen for
PIP in older patients admitted to hospital. Gallagher
et al25 reported lower (p<0.001) proportions of patients
in the intervention group compared with the control
group with one or more STOPP criteria medications for
each of the postintervention assessments (discharge, 2, 4
and 6 months postdischarge). Dalleur et al26 reported no
difference in the proportion of patients with one or
more STOPP criteria medications from hospital admis-
sion to discharge between the intervention and control
groups (OR 1.5, 95% CI 0.49 to 4.89, p=0.454).
However, at group level, the discontinuation rate of
potentially inappropriate medications as identiﬁed using
STOPP criteria was higher in the intervention group
compared with the control group (OR 2.75, 95% CI
1.22 to 6.24, p=0.013). Data from these studies were not
pooled because participants were not homogeneous.
In the Gallagher et al25 study, the Screening Tool to
Alert doctors to Right Treatment (START) criteria were
also used. For each of the postintervention assessments
(discharge, 2, 4 and 6 months postdischarge), lower
Figure 2 Risk of bias in included studies (n=12).
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Table 2 Summary of findings table
Effect estimate
Outcome
Number of
studies
Number of
participants Usual care Pharmaceutical care
Quality of the
evidence
(GRADE
approach) Comments
Summated MAI score
(postintervention)
5 (27–31) 965 Mean summated MAI
score ranged across
control groups from 6.5
to 19.3
Mean summated MAI score in
the intervention groups was 3.88
lower (5.4 to 2.35 lower)
Low*†
Change in MAI score
(from baseline to
follow-up)
4
(27 28 31 33)
424 Mean change in MAI
score ranged across
control groups from
0.41 to 2.86
Mean change in MAI score in
the intervention groups was 6.78
lower (12.34 to 1.22 lower)
Very low*†‡§ A sensitivity analysis showed
that the mean change in MAI
score in the intervention group
was 1.79 lower (3.73 lower to
0.16 higher)¶
Number of Beers drugs
per patient
(post-intervention)
2 (30 31) 586 Mean number of Beers
drugs per participant
ranged across control
groups from 0.04 to 0.4
Mean number of Beers drugs
per participant in the intervention
groups was 0.1 lower (0.28
lower to 0.09 higher)
Very low*‡§
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
*Limitations in the design of studies included in the analysis such as lack of protection against contamination and lack of allocation concealment resulted in downgrading of the quality of
evidence.
†A validated assessment of underprescribing was not included in all studies; therefore, the findings answered a restricted version of the research question. This resulted in downgrading of the
quality of evidence.
‡Statistically significant heterogeneity, variation in effect estimates and non-overlapping CIs between studies resulted in downgrading of the quality of evidence.
§Imprecision in effect estimates was observed whereby CIs were wide and/or crossed the line of no effect.
¶Two studies were excluded from the analysis because of a unit of analysis error33 and an outlying effect estimate with a high risk of bias.31
GRADE, Grades of Recommendation, Assessment, Development and Evaluation; MAI, Medication Appropriateness Index.
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proportions of patients with one or more START criteria
medications were reported in the intervention group
compared with the control group (p<0.001). This was
the only study that used these criteria; therefore,
meta-analysis was not possible.
Assessment of Underutilisation of Medication
Two studies assessed under-use of medication using the
Assessment of Underutilisation of Medication (AUM)
index.25 30 Gallagher et al25 reported a greater reduction
in the proportion of intervention group patients with
prescribing omissions postintervention (by the AUM
index) compared with the control group (absolute risk
reduction 21.2%, 95% CI 13.3% to 29.1%). Schmader
et al30 reported a reduction in the number of conditions
with omitted drugs postintervention in the intervention
group relative to the control group; the difference in
change in AUM score was −0.3 (p<0.0001). As each
study assessed underprescribing on two different levels
(ie, patient, medical condition), meta-analysis was not
possible.
ACOVE
Spinewine et al31 reported that the magnitude of the
reduction in Assessing Care of Vulnerable Elderly
(ACOVE) scores was greater in the intervention group
(baseline score: 50.0, postintervention score: 14.6,
p<0.001) compared with the control group (baseline
score: 58.9, postintervention score: 44.4, p=0.02).
Intervention patients were six times more likely than
control patients to have at least one prescribing improve-
ment based on these criteria (OR 6.1, 95% CI 2.2 to
17.0). Meta-analysis was not possible; no other studies
used this outcome measure.
Hospital admissions
Five studies measured hospital admissions.25 28 31 32 35
Two studies25 31 reported no difference in hospitalisa-
tions between intervention and control groups at
follow-up and the remaining studies reported some
overall reductions in hospital admissions between the
two groups. The statistical signiﬁcance of these reduc-
tions varied based on the methods of assessment
employed in the individual studies. Owing to differences
in the measurement of hospital admissions and the
expression of results, meta-analysis was not possible.
Secondary outcomes
Meta-analysis of secondary outcome assessments was not
possible due to differences across studies in design and
reporting. Evidence of the effect of the interventions on
medication-related problems (six studies)28–30 32 35 36
was conﬂicting. One study reported improved adherence
scores in intervention patients.32 No differences in
HRQoL were reported between intervention and
control groups at baseline or follow-up (two
studies).29 32
DISCUSSION
Given the association between polypharmacy and PIP in
older people,11 17 interventions to improve appropriate
polypharmacy in this cohort are of considerable import-
ance. Only two studies were added to the original review,
bringing the total number of studies included in the
updated review to 12. These two additional studies did
not change the conclusions of the original review and
serve to highlight the lack of intervention studies aimed
at improving appropriate polypharmacy in older people
that have been conducted to date. Coupled with the
ﬁndings of Ryan et al,19 it is evident that interventions
targeting polypharmacy are under-researched at both
the level of healthcare provider and recipient.
The included studies aimed to ensure the prescribing
of appropriate medications to older people that
enhanced their quality of life. However, several studies
focused on reducing the number of prescribed medica-
tions without assessing underprescribing and, therefore,
did not consider the overall appropriateness of prescrib-
ing. This needs to be addressed as underprescribing is
common in older populations with variable prevalence
rates depending on medication classes and care set-
tings.39 Nevertheless, the interventions reduced inappro-
priate prescribing with resultant improvements in the
appropriateness of polypharmacy in older patients. For
example, pooled data showed a signiﬁcant reduction in
intervention group patients’ mean MAI score compared
with control group patients (table 2). Assessments involv-
ing other validated tools also showed improvements in
the appropriateness of prescribing. Although these
results are promising and indicate that the interventions
described in this review were successful in improving
appropriate polypharmacy, the clinical impact is not
known. For example, it is unclear to what extent a reduc-
tion in the magnitude of 3.88 in summated MAI score
(a weighted average rating based on 10 assessment cri-
teria) represents a clinically signiﬁcant reduction in the
risk of harm (table 2). This is because the predictive val-
idity of many tools that are currently used to evaluate
prescribing appropriateness has not been established.40
Therefore, the impact of improvements on the overall
appropriateness of prescribing on clinical outcomes is
unclear.
The ﬁndings from our review are consistent with other
reviews for a number of outcomes. For example, a
related Cochrane review of interventions to optimise
prescribing for older people in care homes41 found no
evidence of an intervention effect on ADEs and hospital
admissions. Other studies of interventions conducted
across various settings have also been unable to detect
the effect of pharmaceutical care on these
outcomes.42 43
Despite the uncertainty as to the effect of the identi-
ﬁed interventions to improve appropriate polypharmacy
on a number of outcome measures, this review provides
useful guidance for the direction of future research.
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Strengths and weakness of this review
The updated Cochrane systematic review that is sum-
marised in this paper represents the most comprehen-
sive overview, using a rigorous methodology, of the
existing body of evidence of the effectiveness of inter-
ventions aimed at improving appropriate polypharmacy
in older patients. Previous reviews have assessed inter-
ventions targeting medication use in older people, but
have not focused on polypharmacy or exclusively used
validated assessment tools.7 44 No language restrictions
were placed on the search strategy and all of the studies
were published in English, including those studies that
were conducted in countries where English is not the
ﬁrst language. Despite the small number of included
studies, no apparent publication bias was detected.
Overall, the included studies were limited by their
small sample sizes and poor quality, with little opportun-
ity to pool data. There was evidence of potential biases
(ﬁgure 2) in the studies which may have inﬂuenced the
reported effect estimates. Although improvements in
appropriate polypharmacy were noted, the ﬁndings of
meta-analyses relating to MAI scores should be treated
cautiously, as the intervention did not seem to work con-
sistently across all studies.
It must also be noted that assessments were based on
surrogate markers and the clinical signiﬁcance of these
improvements in terms of clinically relevant outcomes,
for example, hospital admissions, is unclear as
meta-analysis was not possible. Several studies focused
on reducing the number of medications, rather than
improving the overall appropriateness of prescribing,
including underprescribing.
Implications for clinical practice and future research
Inappropriate prescribing is highly prevalent and com-
monly associated with polypharmacy in older popula-
tions.11 17 However, rigorous evaluations of interventions
seeking to address this are lacking. The ﬁndings of this
review indicate that pharmaceutical care-based interven-
tions appear to improve appropriate polypharmacy in
older people based on observed reductions in inappro-
priate prescribing, especially when the provision of care
involves a multidisciplinary element.25 27–33 CDS showed
potential as an intervention, although this was evaluated
in only one study.34
Surrogate markers of appropriate polypharmacy were
used as there is no universally applicable tool to assess
the appropriateness of polypharmacy. Despite observed
improvements in prescribing appropriateness, it is
unclear if the identiﬁed interventions resulted in clinic-
ally signiﬁcant improvements, for example, reduction in
medication-related problems. In addition to the above
noted issues with the predictive validity of existing tools
for assessing appropriate prescribing, many studies did
not assess outcomes such as adherence, hospitalisations
and quality of life, which are arguably the critical out-
comes for patients and some studies may have lacked
sufﬁcient follow-up periods to detect any signiﬁcant
changes. Future studies should focus on these types of
clinical outcomes.
Overall, the quality and reporting of included studies
was poor. Future research should pay greater attention
to available guidance on intervention development and
evaluations45 to ensure rigour in study design. Methods
of specifying and reporting complex interventions,46 as
well as their implementation strategies, are necessary to
strengthen the evidence base required for interventions
to be more effective, implementable and replicable
across different settings.47 48
Future studies should use clearer deﬁnitions of appro-
priate polypharmacy because the term ‘polypharmacy’
can be both negative and positive, and this duality of
meaning makes objective research difﬁcult.49 A recent
report by the King’s Fund in the UK6 raised the need to
reconsider current deﬁnitions of polypharmacy due to
the increasing numbers of medications being prescribed
to patients. The publication of this report6 coincided
with the abstract screening process in the update of this
review. Therefore, for the purpose of this update, the
deﬁnition of polypharmacy was not changed from the
original review. However, future updates may need to
reconsider the criteria used to deﬁne polypharmacy.
Development of new, universal, easily applied, valid and
reliable outcome measures to evaluate effectiveness of
interventions should be a priority for future research.
Ideally the measure should be globally applicable across
various healthcare and cultural settings; for example,
STOPP/START are validated instruments that could help
to fulﬁl this need.50 In contrast to other tools, such as the
Beers’ criteria, STOPP/START have been speciﬁcally devel-
oped for use in European countries. Although STOPP/
START-related research is still at a relatively early stage, the
criteria are endorsed by the European Union Geriatric
Medicine Society and set for wider application in future
research.51 The use of STARToffers a promising strategy to
decrease underprescribing39 and could serve to improve
appropriate polypharmacy when combined with STOPP.
CONCLUSIONS
The ﬁndings of an updated Cochrane review that are
summarised in this paper highlight the lack of existing
intervention studies of suitable quality aimed at improv-
ing the appropriate use of polypharmacy in older
patients. Overall, the interventions included in this
review demonstrated beneﬁts in this respect based on
observed reductions in inappropriate prescribing.
However, it remains unclear if interventions resulted in
clinically signiﬁcant improvements in terms of hospital
admissions, medication-related problems and patients’
overall quality of life. Future studies would beneﬁt from
guidance relating to intervention development, evalu-
ation and reporting. In addition, more detailed and sys-
tematic reporting of interventions in published papers
could facilitate replication of effective interventions and
uptake into clinical practice.
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